5-methyltetrahydrofolate (5-MTHF)

Developed for: hypertensive disorder
Investigated by: Bozhou people's hospital · Chengdu Fifth People's Hospital · Chizhou people's hospital · Deyang People's Hospital · First Affiliated Hospital of Gannan Medical University · Lianyungang Oriental Hospital
+16 more
· Lianyungang Second People's Hospital · Loudi Central Hospital · Peking University First Hospital · Second Affiliated Hospital of Nanchang University · Shenzhen Ausa Pharmed Co.,Ltd · Shenzhen Prospective Medical Technology Co., LTD · TAIHE country people's hospital · Tengzhou Central People's Hospital · The Affiliated Hospital Of Guizhou Medical University · The Affiliated Hospital Of Southwest Medical University · The First Affiliated Hospital of Bengbu Medical University · The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine · The First People's Hospital of Lianyungang · Weinan Central Hospital · Yancheng First People's Hospital · Yangjiang People's Hospital

today NCT04974151 · Ph 4

20252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT04974151	Aug 2024 → Jun 2029 expected	hyperhomocysteinemia, hypertensive disorder	Shenzhen Ausa Pharmed Co.,Ltd	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	5-methyltetrahydrofolate (5-MTHF)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04974151 ↗
Route	Oral	“5-methyltetrahydrofolate 0.2mg x2 tablets + amlodipine (dummy) x1 tablet, taken orally, in the morning after waking up” NCT04974151 ↗